ISRCTN45338135进行中（未招募）1 期
Phase I trial: PXL 272092
Hansa Biopharma (Sweden)0 个研究点目标入组 8 人开始时间: 2022年5月20日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •Healthy human volunteer
排除标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
1 期
Phase I trial - 2021-006930-37The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has endedISRCTN15751828Omeros Corporation (United States)12
进行中（未招募）
1 期
Phase I trial: QSC206159Healthy volunteersISRCTN51392723Oxilio Limited12
进行中（未招募）
1 期
Phase I trial: Parexel code: PXL 269850ISRCTN12117857MD Pharma88
进行中（未招募）
1 期
Phase 1 trial, HMR code: 21-004The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.Not SpecifiedISRCTN12926361Gedeon Richter Plc104
已完成
1 期
Phase I trial: Labcorp Drug Development Study: 8479217The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN14340698Bergenbio ASA6